XTLB XTL Biopharmaceuticals Ltd ADR

USD 2.81 0.11 4.074074
Icon

XTL Biopharmaceuticals Ltd ADR (XTLB) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.81

+0.11 (+4.07)%

USD 0.02B

0.23M

N/A

N/A

Icon

XTLB

XTL Biopharmaceuticals Ltd ADR (USD)
COMMON STOCK | NSD
USD 2.81
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 2.81

XTL Biopharmaceuticals Ltd ADR (XTLB) Stock Forecast

N/A

Based on the XTL Biopharmaceuticals Ltd ADR stock forecast from 0 analysts, the average analyst target price for XTL Biopharmaceuticals Ltd ADR is not available over the next 12 months. XTL Biopharmaceuticals Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of XTL Biopharmaceuticals Ltd ADR is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, XTL Biopharmaceuticals Ltd ADR’s stock price was USD 2.81. XTL Biopharmaceuticals Ltd ADR’s stock price has changed by +16.12% over the past week, +251.25% over the past month and +117.83% over the last year.

No recent analyst target price found for XTL Biopharmaceuticals Ltd ADR
No recent average analyst rating found for XTL Biopharmaceuticals Ltd ADR

Company Overview XTL Biopharmaceuticals Ltd ADR

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and...Read More

https://www.xtlbio.com

5 Badner Street, Ramat Gan, Israel, 5218102

0

December

USD

USA

Adjusted Closing Price for XTL Biopharmaceuticals Ltd ADR (XTLB)

Loading...

Unadjusted Closing Price for XTL Biopharmaceuticals Ltd ADR (XTLB)

Loading...

Share Trading Volume for XTL Biopharmaceuticals Ltd ADR Shares

Loading...

Compare Performance of XTL Biopharmaceuticals Ltd ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for XTLB

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To XTL Biopharmaceuticals Ltd ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.69 (+0.17%) USD107.38B 29.93 21.06

ETFs Containing XTLB

Symbol Name XTLB's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About XTL Biopharmaceuticals Ltd ADR (XTLB) Stock

Stock Target Advisor's fundamental analysis for XTL Biopharmaceuticals Ltd ADR's stock is Bearish.

Unfortunately we do not have enough data on XTLB's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on XTLB's stock to indicate what its average analyst target is.

XTLB stock's Price/Earning ratio is 4.65. Our analysis grades XTLB stock's Price / Earning ratio at F. This means that XTLB stock's Price/Earning ratio is above 47% of the stocks in the Biotechnology sector in the NSD exchange. Based on this XTLB may be fairly valued for its sector

The last closing price of XTLB's stock was USD 2.81.

The most recent market capitalization for XTLB is USD 0.02B.

Unfortunately we do not have enough analyst data on XTLB's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains XTL Biopharmaceuticals Ltd ADR's stock.

As per our most recent records XTL Biopharmaceuticals Ltd ADR has 0 Employees.

XTL Biopharmaceuticals Ltd ADR's registered address is 5 Badner Street, Ramat Gan, Israel, 5218102. You can get more information about it from XTL Biopharmaceuticals Ltd ADR's website at https://www.xtlbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...